Axsome Therapeutics Inc

Axsome Therapeutics signaled a pipeline cadence of roughly one new drug application filing per year through 2030, with its AXS-12 for cataplexy in narcolepsy receiving a PDUFA target action date of May 1, 2027. The company reported second-quarter 2026 net product revenue of $218 million, a 46% increase from the prior year, driven by AUVELITY and SUNOSI. AUVELITY net product sales reached $180.3 million, SUNOSI net product revenue was $35.8 million, and SYMBRAVO net sales were $2.3 million, though SYMBRAVO faced gross-to-net discount pressure that pushed the metric into the high 80% range due to a prior-period adjustment and patient service utilization. Management expects SYMBRAVO gross-to-net to normalize for the remainder of the year and reiterated that its current cash balance of approximately $320 million is sufficient to fund operations into cash flow positivity. Early launch metrics for AUVELITY in Alzheimer’s disease agitation showed a 126% increase in new-to-brand prescriptions among patients 65 and older during the first eight weeks compared to the same period in the prior quarter.

The Alzheimer's disease market across the seven major markets was valued at approximately USD 4 billion in 2025 and is projected to expand at a CAGR of 22.7% through 2036, according to DelveInsight. The growth is driven by increasing disease prevalence, broader adoption of disease-modifying therapies, advancements in biomarker-based diagnosis, and a robust late-stage pipeline. Key emerging therapies include Masupirdine from Suven Life Sciences, Roche's Trontinemab, Annovis Bio's Buntanetap, AB Science's Masitinib, Eli Lilly's Remternetug, Axsome Therapeutics' AUVELITY, Biovie's Bezisterim, ALZHEON's Valiltramiprosate, TauRx Therapeutics' Hydromethylthionine mesylate, Bristol Myers Squibb's COBENFY, AriBio's AR1001, Acadia Pharmaceuticals' Remlifanserin, and Cerecin's Tricaprilin. The report highlights six late-stage candidates poised to enter the market, including Masupirdine, Trontinemab, AXS-05, COBENFY, Remternetug, and Buntanetap, each with distinct mechanisms of action and anticipated clinical milestones.

Jazz Pharmaceuticals is refocusing its sleep-disorder franchise after Axsome Therapeutics disclosed an FDA filing for AXS-12 in narcolepsy, highlighting Sunosi's move from Jazz's portfolio. Jazz shares have returned 119.3% over the past year and 42.3% over five years, with a 9.1% gain in the last month. The stock closed at $247.53, about 6% below the average analyst target, while Simply Wall St estimates a fair value of $257.00, suggesting the stock is slightly undervalued. Expected approvals for dordaviprone in H3 K27M-mutant diffuse glioma and Zepzelca in first-line small cell lung cancer maintenance are seen as key growth drivers, though risks include patent expirations and reliance on a few pipeline launches.

Axsome Therapeutics is the better growth buy over Revolution Medicines right now, according to a Motley Fool analysis. Axsome already has three commercialized products—Auvelity, Sunosi, and Symbravo—and recently won two new approvals, driving double-digit revenue gains. Its late-stage pipeline includes five phase 3 programs and a regulatory submission for AXS-12 in narcolepsy. Revolution Medicines, while promising, is earlier-stage with no marketed products, and its stock has surged 135% in the first half, suggesting better buying opportunities may come on a dip. Axsome’s nearer-term growth prospects and room for further stock appreciation make it the preferred choice.

Axsome Therapeutics reported strong double-digit product revenue growth in its latest quarter, with Auvelity revenue soaring 59% to $153 million and Sunosi revenue climbing 34% to $33 million. The company recently won approval for Auvelity to treat agitation associated with Alzheimer’s disease and launched Symbravo for migraine relief, with doctors writing about 17,000 prescriptions for Symbravo in the first quarter. Axsome also has a late-stage pipeline that includes AXS-12 for narcolepsy under regulatory review and solriamfetol in phase three trials for four indications. Despite the growth, a $1,000 investment would need a 500% gain to reach $6,000, implying a trillion-dollar market value for Axsome, making it unlikely to be a millionaire-maker stock on its own.

Axsome Therapeutics has dosed the first patient in its FOCUS-3 Phase 3 trial evaluating solriamfetol as a treatment for adolescents with attention deficit hyperactivity disorder. The randomized, double-blind, placebo-controlled, multicenter study will enroll approximately 468 patients aged 12 to less than 18 years, randomized equally to one of two doses of solriamfetol or placebo for six weeks. The primary endpoint is the change from baseline to week 6 in the ADHD Rating Scale total score. Solriamfetol is a dopamine and norepinephrine reuptake inhibitor also being developed for major depressive disorder with excessive daytime sleepiness, binge eating disorder, and shift work disorder.